Jun 4, 2024, 05:00 AM by User Not Found

Bio-IT World | The Oxford Nanopore vision was of a “new generation of single-strand sequencing technology, featuring accurate long reads of single-stranded DNA molecules,” Bio-IT World reported from the 2012 event. Today, Brown’s big ideas include whole-chromosome sequencing, flow cell loading without a pipette, and advances in chemistry, electrical engineering, and commercial format.

Jun 3, 2024, 07:31 AM by

Qlucore to receive a prestigious EIC Accelerator grant of 2,5 million Euros to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer.

May 31, 2024, 08:37 AM by

May 31, 2024, 08:37 AM by

We wanted to reach out today with some exciting, breaking news. 4D Path, a company dedicated to personalizing cancer care through their advanced approach to predicting tumor response announced this morning new clinical data regarding the efficacy of their patented Q-Plasia OncoReader (QPOR) platform, highlighted in two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. "This is an exciting moment for oncology and pathology," said Stuart J. Schnitt, M.D., Chief of Breast Oncologic Pathology for the Dana-Farber Brigham Cancer Center, Associate Director of the Dana-Farber Cancer Institute/Brigham and Women's Hospital Breast Oncology Program. "The 4D Path QPOR Platform can potentially help inform researchers and clinicians about which patients are more or less likely to respond to neoadjuvant chemotherapy, paving the path for more precise and personalized treatments for patients." For the first time ever, we can unveil the dynamics of the tumor microenvironment, allowing biopharma and clinicians to get more targeted and precise in the development of therapies and treatment plans. Not only that, but the profound effects this will have on clinical trials and patient stratification, the benefits to pathologists and clinicians on the front lines with patients, and to patients – not only getting more targeted treatments but also helping the people who would have not responded, more effectively get to a treatment plan that might work. This is a monumental step forward in oncology. We would love to connect you with Satabhisa Mukhopadhyay, PHD, Chief Scientific Officer and Co-Founder of 4D Path, to provide more commentary regarding the importance of this moment and how their innovative, human approach (no AI, no machine learning) is allowing us to be more effective and specific when developing and implementing treatments. We would also be happy to discuss submitting an article authored by Satabhisa discussing these topics, and connect you with industry experts like Dr. Schnitt as well. We have placed below the press release for your reference. Please let us know if you have any questions. We are always available. Look forward to hearing from you.

May 30, 2024, 08:23 AM by

May 30, 2024, 08:23 AM by

PathAI, a global leader in AI-powered pathology, unveiled two novel AI products, PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore1™ to empower cancer drug developers and clinical researchers with AI-powered insights. The product pairing provides unprecedented single-cell and spatial resolution of the tumor microenvironment from routine pathology samples to facilitate biomarker discovery and deeper understanding of treatment response for the next generation of cancer therapeutics. The expansion of the Explore™ portfolio comes at a time when AI-pathology is experiencing accelerated large-scale adoption across the diagnostic and biopharma industries.

May 30, 2024, 08:23 AM by

May 30, 2024, 08:20 AM by

Sakura Finetek Europe announces the launch of its newest advancement in tissue sample identification bringing laboratory workflows to the next level.

May 30, 2024, 08:20 AM by

May 30, 2024, 08:20 AM by

Indica Labs announced today the release of the transformative new version of its industry leading life sciences software.

May 30, 2024, 05:00 AM by User Not Found

Bio-IT World | A consortium of pancreatic cancer researchers sharing information in real time has shown that an oral pan-RAS inhibitor known as RMC-7977, developed by Revolution Medicines, effectively targets the common cancer-causing RAS proteins while minimally impacting normal cells—and did so across a comprehensive range of preclinical models in a series of similar experiments.

May 29, 2024, 05:00 AM by User Not Found

Bio-IT World | Ambry Genetics and PacBio to support the Pediatric Mendelian Genomics Research Center (MGRC) program to better understand the underlying biology of rare diseases; Recursion’s BioHive-2 was dubbed No. 35 on the latest TOP500 list of the world’s fastest supercomputers; the Catalogue of Somatic Mutations in Cancer (COSMIC) launches its 100th version; more.

May 28, 2024, 15:07 PM by

May 28, 2024, 15:07 PM by

May 28, 2024, 15:07 PM by

New independent study’s findings presented during Presidential Plenary session at Digestive Disease Week 2024.

May 28, 2024, 15:07 PM by

May 28, 2024, 15:07 PM by

May 28, 2024, 15:07 PM by

May 28, 2024, 05:00 AM by User Not Found

Bio-IT World | Laurence Belfer gifts funds to MD Anderson Cancer Center to strengthen neurodegeneration research through the Belfer Neurodegeneration Consortium; CN Bio plans to accelerate its expanding product portfolio; more.

May 24, 2024, 07:39 AM by

PathAI, a global leader in AI-powered pathology, and Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced a multi-year strategic partnership to develop curated multimodal datasets that pair PathAI’s PathExplore1 artificial intelligence (AI) tumor microenvironment (TME) quantification panel with Aster Insights’ Avatar clinical, molecular, and digital pathology imaging data. By combining their respective best-in-class platforms, PathAI and Aster Insights will be able to expedite the development of novel insights to accelerate the discovery and development of new treatments for patients with cancer.